PI3K-Akt信号通路与肿瘤化疗耐药性

国际肿瘤学杂志››2014,Vol. 41››Issue (5): 324-327.doi:10.3760/cma.j.issn.1673-422X.2014.05.002

PI3K-Akt信号通路与肿瘤化疗耐药性

姜蓬垒,常冰梅

030001太原，山西医科大学生物化学与分子生物学教研室

收稿日期:2013-12-24修回日期:2014-02-18出版日期:2014-05-08发布日期:2014-04-28
通讯作者:常冰梅 E-mail:cbmcn@163.com

PI3K-Akt signaling pathway and chemotherapy drug resistance in cancer

Jiang Penglei, Chang Bingmei

Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan 030001, China

Received:2013-12-24Revised:2014-02-18Online:2014-05-08Published:2014-04-28
Contact:Chang Bingmei E-mail:cbmcn@163.com

摘要/Abstract

摘要：磷脂酰肌醇3-激酶-蛋白激酶B（PI3K-Akt）信号通路对于细胞增殖、分化、凋亡的调节起关键性作用，与细胞的生理功能和某些疾病的发生关系密切。在许多肿瘤中，PI3K-Akt信号通路的过度激活与肿瘤耐药性的产生也密切相关。体外研究表明，使用化疗药物联合PI3K-Akt信号通路抑制剂，可以显著增强化疗药物作用效果、降低IC50值。因此，PI3K-Akt信号通路已成为一个可以逆转化疗耐药的重要靶点。

关键词:信号传导,肿瘤,药物耐受性,药物疗法

Abstract:PI3K-Akt signaling pathway plays a critical role in the regulation of cell proliferation, differentiation and apoptosis, and is closely related to the physiological function of cells and thus may cause certain diseases. The excessive activation of this pathway is found closely associated with the formation of drug resistance of tumors. Recent studies in vitro indicate that the combined chemotherapy drugs with PI3K-Akt signaling pathway inhibitors, can significantly enhance the efficiency of chemotherapy drug and lower the value of IC50. Therefore, PI3KAkt signaling pathway has become an important target to inhibit tumor cell growth and reverse tumor drug resistance.

Key words:Signal transduction,Neoplasms,Drug tolerance,Drug therapy

姜蓬垒,常冰梅. PI3K-Akt信号通路与肿瘤化疗耐药性[J]. 国际肿瘤学杂志, 2014, 41(5): 324-327.

Jiang Penglei, Chang Bingmei. PI3K-Akt signaling pathway and chemotherapy drug resistance in cancer[J]. Journal of International Oncology, 2014, 41(5): 324-327.

参考文献

［1］ Wu K, Chang Q, Lu P, et al. Gefitinib resistance resulted from STAT3mediated Akt activation in lung cancer cells［J］. Oncotarget, 2013, 4(12):2430-2438. ［2］ Boreddy SR, Pramanik KC, Srivastava SK. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/Akt/FOXO pathway［J］. Clin Cancer Res, 2011, 17(7): 1784-1795. ［3］ Cheng X, Xia W, Yang JY, et al. Activation of MDM2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis［J］. Cancer Res, 2010, 70(19): 7684-7689. ［4］ Koti M, Gooding RJ, Nuin P, et al. Identification of the IGF1/PI3K/NFκB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in highgrade serous epithelial ovarian cancer［J］. BMC Cancer, 2013,13:549. ［5］ Zhang HR, Chen JM, Zeng ZY, et al. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI8226 cells via inhibiting PI3K/Akt activity［J］. J Int Med Res, 2013, 41(3):584-595. ［6］ Juengel E, Makarevi′c J, Tsaur I, et al. Resistance after chronic application of the HDACinhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo［J］. PLoS One, 2013, 8(1):1-6. ［7］ He C, Sun XP, Qiao H, et al. Downregulating hypoxiainducible factor2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma［J］. Cancer Sci, 2012, 103(3):528-534. ［8］ KilicEren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia inducible factor1alpha activation and sensitizes Rhabdomyosarcoma and Ewing′s sarcoma cells for apoptosis［J］. Cancer Cell Int, 2013, 13(1):36. ［9］蔡彦韬, 杨逸, 项建斌, 等. PIK3CA基因与结直肠癌发生发展的研究［J］. 国际肿瘤学杂志, 2012, 39(9):693-696. ［10］ Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy［J］. Clin Cancer Res, 2009, 15(8):2583-2587. ［11］ Chou CH, Lai SL, Chen CN, et al. IL6 regulates Mcl1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an antiapoptotic role during liver regeneration［J］. PLoS One, 2013, 8(6):e66268. ［12］ Balwani S, Chaudhuri R, Nandi D, et al. Regulation of NFκB activation through a novel PI3Kindependent and PKA/Aktdependent pathway in human umbilical vein endothelial cells［J］. PLoS One, 2012, 7(10):e46528. ［13］ Caporali S, Levati L, Graziani G, et al. NFκB is activated in response to temozolomide in an Aktdependent manner and confers protection against the growth suppressive effect of the drug［J］. J Transl Med, 2012, 10:252. ［14］ Sakamaki J, Daitoku H, Ueno K, et al. Arginine methylation of BCL2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt［J］. Proc Natl Sci USA, 2011, 108(15):6085-6090. ［15］ Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stemlike cells［J］. Cell Stem Cell, 2009, 4(3):226-235. ［16］ Kufe DW. Functional targeting of the MUC1 oncogene in human cancers［J］. Cancer Biol Ther, 2009, 8(13):1197-1203. ［17］ Nath S, Daneshvar K, Roy LD, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes［J］. Oncogenesis, 2013, 2: e51. ［18］ Zielinski R, Przytycki PF, Zheng J, et al. The crosstalk between EGF, IGF, and Insulin cell signaling pathwayscomputational and experimental analysis［J］. BMC Syst Biol, 2009, 3:88. ［19］ Gedaly R, Angulo P, Hundley J, et al. PI103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/Akt/mTOR pathways［J］. Anticancer Res, 2010, 30(12):4951-4958. ［20］ Fang X, Jiang Y, Feng L, et al. Blockade of PI3K/Akt pathway enhances sensitivity of Raji cells to chemotherapy through downregulation of HSP70［J］. Cancer Cell Int, 2013, 13(1):48. ［21］ Gao AM, Ke ZP, Shi F, et al. Chrysin enhances sensitivity of BEL7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway［J］. Chem Biol Interact, 2013, 206(1):100-108. ［22］ Sims JT, Ganguly SS, Bennett H, et al. Imatinib reverses doxorubicin resistance by affecting activation of STAT3dependent NFκB and HSP27/p38/Akt pathways and by inhibiting ABCB1［J］. PLoS One, 2013, 8(1):e55509.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.